Concerto Biosciences

Executive Summary

Concerto Biosciences is a private biotechnology company founded in 2020 that leverages its proprietary kChip and kAI platform to discover and develop multifunctional microbial ingredients for consumer skin health and therapeutic applications. The company's approach involves measuring, mapping, and harnessing microbial ecology to create safe and effective products. Concerto's lead candidate, ENS-002, was evaluated in a Phase 1 clinical trial (NCT06469385) for atopic dermatitis, but the trial was terminated in August 2025. Despite this setback, the company's platform remains promising for identifying microbial consortia with broad applications in dermatology and beyond. The company is headquartered in Cambridge, Massachusetts, and operates in the microbiome sector. Given the early stage and recent clinical termination, Concerto's near-term outlook depends on its ability to redirect its pipeline or secure partnerships for its platform technology. The company has not disclosed its total funding or valuation, but its innovative approach to microbial ecology positions it as a potential player in the growing microbiome therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new lead indication or partnership following ENS-002 termination40% success
• Q4 2026Release of preclinical data for a next-generation microbial consortia candidate50% success
• TBDSeries A or B financing round to support platform development45% success